Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
OrbusNeich Medical Group Holdings Limited (6929.HK)
Sha Tin, HK
OrbusNeich Medical Group Holdings Limited functions as an investment holding entity, specializing in the development, distribution, sales, and marketing of medical instruments tailored for treating coronary and peripheral vascular ailments. The company boasts a significant international presence, serving markets across Japan, Europe, the Middle East, Africa, the Asia Pacific region, the People's Republic of China, and the United States. Its product offerings encompass a range of essential devices, including semi-compliant and scoring balloons used for initial vessel preparation, coronary stents for implantation, non-compliant balloons designed for post-dilatation, and a variety of specialized catheters. This extensive portfolio of products addresses critical steps within percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Founded in 2001, the company is headquartered in Shatin, Hong Kong, and operates as a subsidiary of Harmony Tree Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.71% | -1.17% | +11.32% | +17.50% | +4.44% | +16.85% | +12.50% | -62.57% | -53.77% | -53.77% | -53.77% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+10.0% ★ Q4'25: +33.7% (vs Q4'23)
-
EPS growth Medical - Instruments & Supplies: +16.3%+5.6% Q4'25: +12.6% (vs Q4'23)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+6.1% ★ Q4'25: +12.3% (vs Q4'23)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+21.8% ★ Q4'25: +24.4% (vs Q4'23)
-
ROIC Medical - Instruments & Supplies: +6.0%+17.6% ★ Q4'25: +40.0% (vs Q4'23)
-
Share dilution Medical - Instruments & Supplies: +0.1%-0.1% ★ Q4'25: -1.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.09× ★ Q4'25: 0.04× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
136.82M
est: 138.18M (-1.0%)
|
153.87M
est: 149.49M (+2.9%)
|
164.10M
est: 164.00M (+0.1%)
|
180.45M
est: 177.68M (+1.6%)
|
200.23M
199.37M – 201.09M
+12.7% YoY
|
219.88M
216.48M – 223.29M
+9.8% YoY
|
238.63M
236.21M – 241.06M
+8.5% YoY
|
| EBITDA |
27.14M
est: 55.53M (-51.1%)
|
53.97M
est: 60.08M (-10.2%)
|
36.76M
est: 62.87M (-41.5%)
|
42.78M
est: 68.12M (-37.2%)
|
76.76M
76.43M – 77.09M
+12.7% YoY
|
84.30M
82.99M – 85.60M
+9.8% YoY
|
91.49M
90.56M – 92.41M
+8.5% YoY
|
| EBIT |
23.25M
est: 51.87M (-55.2%)
|
49.76M
est: 56.12M (-11.3%)
|
34.82M
est: 62.56M (-44.3%)
|
39.34M
est: 67.78M (-42.0%)
|
76.38M
76.05M – 76.71M
+12.7% YoY
|
83.88M
82.58M – 85.18M
+9.8% YoY
|
91.03M
90.11M – 91.96M
+8.5% YoY
|
| Net Income |
18.49M
est: 26.45M (-30.1%)
|
45.07M
est: 41.27M (+9.2%)
|
39.72M
est: 49.53M (-19.8%)
|
41.90M
est: 41.28M (+1.5%)
|
42.81M
42.24M – 43.37M
+3.7% YoY
|
48.63M
47.99M – 49.27M
+13.6% YoY
|
50.71M
50.04M – 51.37M
+4.3% YoY
|
| SGA |
55.13M
est: 53.84M (+2.4%)
|
54.84M
est: 58.25M (-5.9%)
|
62.70M
est: 63.78M (-1.7%)
|
67.38M
est: 69.10M (-2.5%)
|
77.87M
77.54M – 78.21M
+12.7% YoY
|
85.52M
84.20M – 86.84M
+9.8% YoY
|
92.81M
91.87M – 93.75M
+8.5% YoY
|
| EPS |
0.03
est: 0.03 (-1.1%)
|
0.05
est: 0.05 (+8.2%)
|
0.05
est: 0.06 (-19.8%)
|
0.05
est: 0.05 (+1.8%)
|
0.05
0.05 – 0.05
+3.7% YoY
|
0.06
0.06 – 0.06
+13.6% YoY
|
0.06
0.06 – 0.06
+4.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-28 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-27 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-26 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-22 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-21 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-20 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-19 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-18 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-15 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-14 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-13 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-12 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-11 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-08 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-05 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-04 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-30 | A+ | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-29 | A+ | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-28 | A+ | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-27 | A+ | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap ETF DFIS | 0.00% | 18.2K | 0.39% |
| 2 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 10.2K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David Chien | Chairman of the Board & Chief Executive Officer | 9M | male |
| Kwai Ching Lau | Chief Operating Officer & Executive Director | 7M | female |
| Wing Shing Chen | Chief Financial Officer, Company Secretary & Executive Director | 5M | male |
| Alain Djamel Khair | Chief Commercial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6929.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
